Besides, a recent retrospective study evaluated the efficacy and safety of triplet regimen of VP-16 with AraC plus G-CSF as a novel mobilization regimen in MM patients and reported that this combination was highly efficient in high-risk MM patients who were referred for tandem ASCT [57]. This evidence concerns the gene CSF3 and Miyoshi myopathy.